Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company's commercial products include Ritonavir tablet; and ASCLEVIR and GANOVO for use in the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for treating respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, and ASC43F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma; ASC61 for advanced solid tumors; and ASC40, an oral small molecule for the treatment of acne. Further, it offers ASC30, for obesity; ASC47 for muscle-preserving weight loss treatment; and ASC39, a potent and amylin-selective oral small molecule amylin receptor agonist. Ascletis Pharma Inc. was founded in 2013 and is based in Wan Chai, Hong Kong.
Frequently asked questions
What sector does Ascletis Pharma Inc (1672) operate in?
Ascletis Pharma Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Ascletis Pharma Inc (1672) current stock price?
As of the latest data, Ascletis Pharma Inc stock price is HK$8.97, with a previous close of HK$8.15. Ascletis Pharma Inc gained HK$0.83 in the last trading session, representing a 10.13% increase.
What is Ascletis Pharma Inc (1672) current market capitalization?
Ascletis Pharma Inc market cap is approximately 9.42 billion.
What is Ascletis Pharma Inc (1672) EBITDA?
Ascletis Pharma Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -364.30 million.
Does Ascletis Pharma Inc (1672) pay dividends?
No. Ascletis Pharma Inc does not pay a dividend.
What is Ascletis Pharma Inc (1672) beta (volatility) score?
Ascletis Pharma Inc has a beta of 0.392, indicating lower volatility than the overall market.
